Fermion invests $33m to add HPAPI capacity at Hanko plant

By Gareth Macdonald

- Last updated on GMT

Fermion facility in Hanko, set for expansion (source Fermion website)
Fermion facility in Hanko, set for expansion (source Fermion website)

Related tags Pharmacology

Fermion will invest €30m ($33m) to expand its API facility in Hanko, Finland to build its high potency drug ingredient manufacturing business.

The firm said the expansion – which is due to be completed in 2018 – will increase reactor capacity to around 400m3 and introduce isolators and containment technologies.

Around 25m3 of the new reactor capacity will be dedicated to the production on Occupational exposure banding 5 (OEB5) classified high potency active pharmaceutical ingredients (API), which require a containment level of 0,1 µg/m3.

Company president Arto Toivonen said: “The expansion lifts Fermion to a new level in the global arena of API and especially HAPI manufacturing, improving Fermion’s capability to meet increasing demand​.”

He added that: “The new unit alone will be able to produce 100 metric tons HPAPI per year increasing the total production capacity of Fermion to over 400 metric tons API/year. Fermion’s scale of HPAPI development and production will now be complete with capabilities from grams to tons​.”

News of the expansion comes a few months after Fermion's other API facility in Oulu passed an inspection by Brazilian regulator, ANVISA.

Fermion passed successfully ANVISA Inspection 2016 with three minor recommendations.

According to Fermion: "The Quality System and Manufacturing Facilities were reviewed and as commented by the Inspector in the summary meeting: 'You have a very good Quality System, we have rarely seen such systematic procedures​'."

Sales decline

Fermion is a subsidiary of Orion Corporation. According to an Orion financial report the API unit generated revenue of €53m in 2015, down 8% year-on-year.

The decline has continued into the first quarter of 2016 according to Orion.

"Fermion’s net sales in January– March 2016 excluding pharmaceutical ingredients supplied for Orion’s own use were down by 28% at €11m and accounted for nearly two-thirds of Fermion’s entire net sales. The decrease was mainly due to the timing of product deliveries​."

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars